Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.

Boulikas T.

Expert Opin Investig Drugs. 2009 Aug;18(8):1197-218. doi: 10.1517/13543780903114168. Review.

PMID:
19604121
2.

Liposomal cisplatin: a new cisplatin formulation.

Stathopoulos GP.

Anticancer Drugs. 2010 Sep;21(8):732-6. doi: 10.1097/CAD.0b013e32833d9adf. Review.

PMID:
20671511
3.

Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.

Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M.

Anticancer Res. 2005 Jul-Aug;25(4):3031-9.

4.
5.
6.
7.

Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.

Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, Viliotou V, Stathopoulos JG.

Oncol Rep. 2005 Apr;13(4):589-95.

PMID:
15756428
8.

Low renal toxicity of lipoplatin compared to cisplatin in animals.

Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M, Boulikas T.

Anticancer Res. 2004 Jul-Aug;24(4):2193-200.

9.

Activity of lipoplatin in tumor and in normal cells in vitro.

Arienti C, Tesei A, Ravaioli A, Ratta M, Carloni S, Mangianti S, Ulivi P, Nicoletti S, Amadori D, Zoli W.

Anticancer Drugs. 2008 Nov;19(10):983-90. doi: 10.1097/CAD.0b013e3283114fb2.

PMID:
18827563
10.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
11.

Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.

[No authors listed]

Drugs R D. 2004;5(4):220-6. Review.

PMID:
15230629
12.
13.

Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.

Casagrande N, De Paoli M, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D.

Gynecol Oncol. 2013 Dec;131(3):744-52. doi: 10.1016/j.ygyno.2013.08.041. Epub 2013 Sep 10.

PMID:
24029417
14.

A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.

Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.

Semin Oncol. 1995 Dec;22(6 Suppl 15):50-4.

PMID:
8643971
15.

New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

Caponigro F, Basile M, de Rosa V, Normanno N.

Anticancer Drugs. 2005 Feb;16(2):211-21.

PMID:
15655420
16.

Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study.

Stathopoulos GP, Rigatos SK, Stathopoulos J.

Anticancer Res. 2010 Apr;30(4):1317-21.

PMID:
20530446
17.
18.

Satraplatin: BMS 182751, BMY 45594, JM 216.

[No authors listed]

Drugs R D. 2007;8(2):125-32. Review.

PMID:
17324011
19.

Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.

O'Malley BW Jr, Li D, McQuone SJ, Ralston R.

Laryngoscope. 2005 Mar;115(3):391-404.

PMID:
15744147
20.

Supplemental Content

Support Center